About Bortecad 2 Mg Injection
Discover the formidable value of Bortecad 2 Mg Injection, a powerful antineoplastic agent recommended for the treatment of multiple myeloma and mantle cell lymphoma. Marketed by Cadila Healthcare Limited, this lyophilized powder boasts instant savings for those seeking cost-effective therapy without compromising efficacy. Its gorgeous white to off-white appearance signals purity and reliability. The valiant formulation, containing 2 mg of bortezomib per vial, is to be administered intravenously or subcutaneously by skilled healthcare professionals. Find peace of mind knowing that each dose is designed and manufactured in India and meets stringent global standards.
Innovative Anticancer Solution for Oncology Care
Bortecad 2 Mg Injection is widely used as a robust treatment option for adults diagnosed with multiple myeloma and mantle cell lymphoma. The material feature includes a lyophilized powder presented in a single-use vial for precise dosing. Notable features include reconstitution with 2.0 ml of 0.9% sodium chloride, white to off-white appearance, and a prescription-only status, ensuring reliable, evidence-based cancer care in controlled medical settings.
International Export Value and Efficient Packaging
Positioned with outstanding market value, Bortecad 2 Mg Injection is available for export via major Indian FOB ports. The packaging details emphasize secure vial containment, maintaining product quality during transit. Outlay and quotation options provide competitive pricing for traders, distributors, and suppliers. Main export markets extend across Asia, Africa, and the Middle East, ensuring this vital pharmaceutical reaches healthcare providers and patients worldwide, supporting global oncology needs.
FAQ's of Bortecad 2 Mg Injection:
Q: How should Bortecad 2 Mg Injection be administered?
A: Bortecad 2 Mg Injection is intended for intravenous or subcutaneous use, and should always be administered by trained healthcare professionals following the prescribed dosage and reconstitution instructions.
Q: What are the main indications for using Bortecad 2 Mg Injection?
A: This injection is primarily indicated for the treatment of multiple myeloma and mantle cell lymphoma in adults, as prescribed by a qualified physician.
Q: When should Bortecad 2 Mg Injection not be used?
A: It should not be administered to individuals with hypersensitivity to bortezomib, boron, or any ingredient in the formulation. Always consult with your doctor regarding possible contraindications.
Q: Where should Bortecad 2 Mg Injection be stored before use?
A: Keep the vial in a dry, cool place below 30C, protected from light, and do not freeze to preserve efficacy until administration.
Q: What are the side effects associated with Bortecad 2 Mg Injection?
A: Common side effects include peripheral neuropathy, thrombocytopenia, fatigue, and gastrointestinal disturbances. Always discuss risk factors and side effects with your healthcare provider before starting therapy.
Q: How does Bortecad 2 Mg Injection interact with other medications?
A: This injection may interact with drugs that are CYP3A4 inhibitors or inducers. Inform your physician about all medications you are taking before starting Bortecad therapy.